In August 2023, Blau Farmacêutica, one of the most important pharmaceutical companies in Latin America, invested in Prothya Biosolutions, a Belgian company, which is one of the 10 largest companies in the plasma fractionation sector, through a convertible loan agreement that granted Blau Farmacêutica the right to convert the investment into an equity interest in the share capital of Prothya Biosolutions. The transaction value was EUR 50 million.